School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Vaccine. 2010 Apr 1;28(16):2806-9. doi: 10.1016/j.vaccine.2009.09.047. Epub 2009 Sep 25.
As history has demonstrated, post-approval obstacles can impede a vaccine's use and potentially lead to its withdrawal. Addressing these potential obstacles when changes in a vaccine's technology can still be easily made may improve a vaccine's chances of success. Augmented vaccine target product profiles (TPPs) can help vaccine scientists better understand and anticipate these obstacles and galvanize conversations among various vaccine stakeholders (e.g., scientists, marketers, business development managers, policy makers, public health officials, health care workers, third party payors, etc.) earlier in a vaccine's development.
正如历史所证明的那样，批准后障碍可能会阻碍疫苗的使用，并可能导致其被撤回。在疫苗技术发生变化时解决这些潜在障碍，可能会提高疫苗成功的机会。增强的疫苗目标产品概况（TPP）可以帮助疫苗科学家更好地理解和预测这些障碍，并在疫苗开发的早期就激发各种疫苗利益相关者（例如科学家、营销人员、业务发展经理、政策制定者、公共卫生官员、卫生保健工作者、第三方支付者等）之间的对话。
